Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients

References

• Ullah MF, Aatif M. The footprints of cancer development: Cancer biomarkers. Cancer Treatment Rev 2009; 35:193-200; PMID:19062197; https://doi.org/10.1016/j.ctrv.2008.10.004
   PubMed Web of Science ®Google Scholar
• Shin HR, Masuyer E, Ferlay J, Curado MP. Asian Contributors to CI. Cancer in Asia - Incidence rates based on data in cancer incidence in five continents IX (1998–2002). Asian Pacific J Cancer Prevention 2010; 11(Suppl 2):11-6; PMID:20553065
   PubMedGoogle Scholar
• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer J Int Du Cancer 2010; 127:2893-917; PMID:21351269; https://doi.org/10.1002/ijc.25516
   PubMed Web of Science ®Google Scholar
• Wang LW, Yang GF, Chen JM, Yang F, Yuan JP, Sun SR, Chen C, Hu MB, Li Y. A clinical database of breast cancer patients reveals distinctive clinico-pathological characteristics: a study from central China. Asian Pacific J Cancer Prevention 2014; 15:1621-6; PMID:24641378; https://doi.org/10.7314/APJCP.2014.15.4.1621
   PubMedGoogle Scholar
• Madani SH, Payandeh M, Sadeghi M, Motamed H, Sadeghi E. The correlation between Ki-67 with other prognostic factors in breast cancer: A study in Iranian patients. Indian J Med Paediatr Oncol 2016; 37:95-9; PMID:27168707; https://doi.org/10.4103/0971-5851.180136
   PubMed Web of Science ®Google Scholar
• Zhou SJ, Guo H. Ki-67 expression and significance of different molecular subtypes of breast invasive ductal carcinoma. Zhonghua Yi Xue Za Zhi 2013; 93:2895-7; PMID:24373403
   PubMedGoogle Scholar
• Misek DE, Kim EH. Protein biomarkers for the early detection of breast cancer. Int J Proteomics 2011; 2011:343582; PMID:22084684
   PubMedGoogle Scholar
• Strauss B. Best hope or last hope: access to phase III clinical trials of HER-2/neu for advanced stage breast cancer patients. J Adv Nursing 2000; 31:259-66; PMID:10672081; https://doi.org/10.1046/j.1365-2648.2000.01302.x
   PubMed Web of Science ®Google Scholar
• Kaufmann R, Muller P, Hildenbrand G, Hausmann M, Cremer C. Analysis of Her2/neu membrane protein clusters in different types of breast cancer cells using localization microscopy. J Microscopy 2011; 242:46-54; PMID:21118230; https://doi.org/10.1111/j.1365-2818.2010.03436.x
   PubMed Web of Science ®Google Scholar
• Petit T, Borel C, Ghnassia JP, Rodier JF, Escande A, Mors R, Haegele P. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res 2001; 7:1577-81; PMID:11410493
   PubMed Web of Science ®Google Scholar
• Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012; 9:16-32; https://doi.org/10.1038/nrclinonc.2011.177
   PubMed Web of Science ®Google Scholar
• Faltus T, Yuan J, Zimmer B, Kramer A, Loibl S, Kaufmann M, Strebhardt K. Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia 2004; 6:786-95; PMID:15720805; https://doi.org/10.1593/neo.04313
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Eng J Med 2001; 344:783-92; PMID:11248153; https://doi.org/10.1056/NEJM200103153441101
   PubMed Web of Science ®Google Scholar
• Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998; 16:413-28; PMID:9831867; https://doi.org/10.1002/stem.160413
   PubMed Web of Science ®Google Scholar
• Hosoda M, Yamamoto M, Nakano K, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y, Yamashita H. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treatment 2014; 144:249-61; PMID:24549642; https://doi.org/10.1007/s10549-014-2867-0
   PubMed Web of Science ®Google Scholar
• Lee DS, Kim SH, Suh YJ, Kim S, Kim HK, Shim BY. Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy. Japanese J Clin Oncol 2011; 41:854-66; PMID:21719749; https://doi.org/10.1093/jjco/hyr066
   PubMed Web of Science ®Google Scholar
• Lane DP, Brown CJ, Verma C, Cheok CF. New insights into p53 based therapy. Discov Med 2011; 12:107-17; PMID:21878188
   PubMed Web of Science ®Google Scholar
• Chen F, Wang W, El-Deiry WS. Current strategies to target p53 in cancer. Biochem Pharmacol 2010; 80:724-30; PMID:20450892; https://doi.org/10.1016/j.bcp.2010.04.031
   PubMed Web of Science ®Google Scholar
• Smeenk L, Lohrum M. Behind the scenes: unravelling the molecular mechanisms of p53 target gene selectivity (Review). Int J Oncol 2010; 37:1061-70; PMID:20878053
   PubMed Web of Science ®Google Scholar
• Wright PE, Dyson HJ. Intrinsically disordered proteins in cellular signalling and regulation. Nat Rev Mol Cell Biol 2015; 16:18-29; PMID:25531225; https://doi.org/10.1038/nrm3920
   PubMed Web of Science ®Google Scholar
• Varna M, Bousquet G, Plassa LF, Bertheau P, Janin A. TP53 status and response to treatment in breast cancers. J Biomed Biotechnol 2011; 2011:284584; PMID:21760703; https://doi.org/10.1155/2011/284584
   PubMedGoogle Scholar
• Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006; 124:207-19; PMID:16413492; https://doi.org/10.1016/j.cell.2005.10.043
   PubMed Web of Science ®Google Scholar
• Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26:2157-65; PMID:17401424; https://doi.org/10.1038/sj.onc.1210302
   PubMed Web of Science ®Google Scholar
• Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49-53; PMID:1905840; https://doi.org/10.1126/science.1905840
   PubMed Web of Science ®Google Scholar
• Anderson E, Clarke RB. Steroid receptors and cell cycle in normal mammary epithelium. J Mammary Gland Biol Neoplasia 2004; 9:3-13; PMID:15082914; https://doi.org/10.1023/B:JOMG.0000023584.01750.16
   PubMed Web of Science ®Google Scholar
• Brisken C. Reply to is progesterone a neutral or protective factor for breast cancer? Nat Rev Cancer 2014; 14:146; PMID:24442144; https://doi.org/10.1038/nrc3518-c2
   PubMed Web of Science ®Google Scholar
• Milde-Langosch K, Karn T, Muller V, Witzel I, Rody A, Schmidt M, Wirtz RM. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer. Breast Cancer Res Treatment 2013; 137:57-67; PMID:23135572; https://doi.org/10.1007/s10549-012-2296-x
   PubMed Web of Science ®Google Scholar
• Denkert C, von Minckwitz G. Reply to Ki67 in breast cancer: a useful prognostic marker. Annals Oncol 2014; 25:542-3; PMID:24431345; https://doi.org/10.1093/annonc/mdt564
   PubMed Web of Science ®Google Scholar
• Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11:174-83; PMID:20152769; https://doi.org/10.1016/S1470-2045(09)70262-1
   PubMed Web of Science ®Google Scholar
• Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, Litton JK, Olopade OI, Hortobagyi GN, Strong LC, et al. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 2012; 118:908-13; PMID:21761402; https://doi.org/10.1002/cncr.26377
   PubMed Web of Science ®Google Scholar
• Rudolph P, Olsson H, Bonatz G, Ratjen V, Bolte H, Baldetorp B, Ferno M, Parwaresch R, Alm P. Correlation between p53, c-erbB-2, and topoisomerase II α expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathol 1999; 187:207-16; PMID:10365096; https://doi.org/10.1002/(SICI)1096-9896(199901)187:2%3c207::AID-PATH223%3e3.0.CO;2-U
   PubMed Web of Science ®Google Scholar
• Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003; 95:142-53; PMID:12529347; https://doi.org/10.1093/jnci/95.2.142
   PubMed Web of Science ®Google Scholar
• Hayes DF, Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 2002; 29:231-45; PMID:12063676; https://doi.org/10.1053/sonc.2002.32899
   PubMed Web of Science ®Google Scholar
• Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JF, Ellis IO, Blamey RW. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 1993; 29A:1018-23; PMID:8098946; https://doi.org/10.1016/S0959-8049(05)80215-1
   PubMed Web of Science ®Google Scholar
• Alco G, Bozdogan A, Selamoglu D, Pilanci KN, Tuzlali S, Ordu C, Igdem S, Okkan S, Dincer M, Demir G, et al. Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients. Oncol Lett 2015; 9:1046-54; PMID:25663855
   PubMed Web of Science ®Google Scholar
• Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocrine-Related Cancer 2010; 17:R245-62; PMID:20647302; https://doi.org/10.1677/ERC-10-0136
   PubMed Web of Science ®Google Scholar
• Shapochka DO, Zaletok SP, Gnidyuk MI. Relationship between NF-kappaB, ER, PR, Her2/neu, Ki67, p53 expression in human breast cancer. Exp Oncol 2012; 34:358-63; PMID:23302996
   PubMedGoogle Scholar
• Sana M, Malik HJ. Current and emerging breast cancer biomarkers. J Cancer Res Therapeutics 2015; 11:508-13; PMID:26458575; https://doi.org/10.4103/0973-1482.163698
   PubMed Web of Science ®Google Scholar
• Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 2004; 101:9393-8; PMID:15194824; https://doi.org/10.1073/pnas.0402993101
   PubMed Web of Science ®Google Scholar
• Espinosa AB, Tabernero MD, Garcia-Macias MC, Primo D, Bernal AG, Cruz JJ, Ramos M, Font de Mora J, Gomez Alonso A, Orfao A. Her-2/neu gene amplification in familial vs sporadic breast cancer. Impact on the behavior of the disease. Am J Clin Pathol 2003; 120:917-27; PMID:14671981; https://doi.org/10.1309/5H778W5K75CMM03W
   PubMed Web of Science ®Google Scholar
• Beckmann MW, Niederacher D, Massenkeil G, Tutschek B, Beckmann A, Schenko G, Schnurch HG, Bender HG. Expression analyses of epidermal growth factor receptor and HER-2/neu: no advantage of prediction of recurrence or survival in breast cancer patients. Oncology 1996; 53:441-7; PMID:8960138; https://doi.org/10.1159/000227618
   PubMed Web of Science ®Google Scholar
• Bebenek M, Bar JK, Harlozinska A, Sedlaczek P. Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement. Anticancer Res 1998; 18:619-23; PMID:9568187
   PubMed Web of Science ®Google Scholar
• Radovic S, Babic M, Doric M, Balta E, Kapetanovic E, Secic S. Correlation of the HER-2 protein expression and other clinicopathological features of ductal infiltrative breast cancer. Bosn J Basic Med Sci 2005; 5:3-7; PMID:15771595
   PubMedGoogle Scholar
• Selvarajan S, Wong KY, Khoo KS, Bay BH, Tan PH. Over-expression of c-erbB-2 correlates with nuclear morphometry and prognosis in breast carcinoma in Asian women. Pathology 2006; 38:528-33; PMID:17393979; https://doi.org/10.1080/00313020601024060
   PubMed Web of Science ®Google Scholar
• Chen ST, Lai HW, Tseng HS, Chen LS, Kuo SJ, Chen DR. Correlation of histologic grade with other clinicopathological parameters, intrinsic subtype, and patients' clinical outcome in Taiwanese women. Jpn J Clin Oncol 2011; 41:1327-35; PMID:22071339; https://doi.org/10.1093/jjco/hyr157
   PubMed Web of Science ®Google Scholar
• Patnayak R, Jena A, Rukmangadha N, Chowhan AK, Sambasivaiah K, Phaneendra BV, Reddy MK. Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience. Indian J Med Paediatr Oncol 2015; 36:117-22; PMID:26157289; https://doi.org/10.4103/0971-5851.158844
   PubMed Web of Science ®Google Scholar
• Elkablawy MA, Albasry AM, Hussainy AS, Nouh MM, Alhujaily A. Molecular profiling of breast carcinoma in Almadinah, KSA: Immunophenotyping and clinicopathological correlation. Asian Pac J Cancer Prev 2015; 16:7819-24; PMID:26625804; https://doi.org/10.7314/APJCP.2015.16.17.7819
   PubMedGoogle Scholar
• Sekar P, Bharti JN, Nigam JS, Sharma A, Soni PB. Evaluation of p53, HoxD10, and E-Cadherin status in breast cancer and correlation with histological grade and other prognostic factors. J Oncol 2014; 2014:702527; PMID:24634677; https://doi.org/10.1155/2014/702527
   PubMedGoogle Scholar
• Sirvent JJ, Salvado MT, Santafe M, Martinez S, Brunet J, Alvaro T, Palacios J. p53 in breast cancer. Its relation to histological grade, lymph-node status, hormone receptors, cell-proliferation fraction (ki-67) and c-erbB-2. Immunohistochemical study of 153 cases. Histol Histopathol 1995; 10:531-9; PMID:7579801
   PubMedGoogle Scholar
• Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Therapeutic Med 2010; 1:747-54; PMID:22993598; https://doi.org/10.3892/etm.2010.133
   PubMed Web of Science ®Google Scholar
• Wang B, Wang X, Wang J, Xuan L, Wang Z, Wang X, Gao J, Zhang H. Expression of Ki67 and clinicopathological features in breast cancer. Zhonghua Zhong Liu Za Zhi 2014; 36:273-5
   PubMedGoogle Scholar
• Golmohammadi R, Pejhan A. The prognostic value of the P53 protein and the Ki67 marker in breast cancer patients. J Pak Med Assoc 2012; 62:871-5; PMID:23139965
   PubMed Web of Science ®Google Scholar
• Elkablawy MA, Albasri AM, Mohammed RA, Hussainy AS, Nouh MM, Alhujaily AS. Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients. Saudi Med J 2016; 37:137-41; PMID:26837394; https://doi.org/10.15537/smj.2016.2.12285
   PubMed Web of Science ®Google Scholar
• Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocrine Rev 2008; 29:217-33; PMID:18216219; https://doi.org/10.1210/er.2006-0045
   PubMed Web of Science ®Google Scholar
• Pinhel I, Hills M, Drury S, Salter J, Sumo G, A'Hern R, Bliss JM, Sestak I, Cuzick J, Barrett-Lee P, et al. ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Res 2012; 14:R46; PMID:22417870; https://doi.org/10.1186/bcr3145
   PubMed Web of Science ®Google Scholar
• Perin T, Canzonieri V, Massarut S, Bidoli E, Rossi C, Roncadin M, Carbone A. Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast. Eur J Cancer 1996; 32A:1148-55; PMID:8758245; https://doi.org/10.1016/0959-8049(96)00037-8
   PubMed Web of Science ®Google Scholar
• Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10:2435-46; PMID:7784095
   PubMed Web of Science ®Google Scholar
• Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, et al. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res 2010; 12:R40; PMID:20569503; https://doi.org/10.1186/bcr2594
   PubMed Web of Science ®Google Scholar
• Kim HJ, Cui X, Hilsenbeck SG, Lee AV. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res 2006; 12:1013s-8s; PMID:16467118; https://doi.org/10.1158/1078-0432.CCR-05-2128
   PubMed Web of Science ®Google Scholar
• Barbati A, Cosmi EV, Sidoni A, Collini P, Porpora MG, Ferri I, Luthy M, Lauro V, Bucciarelli E. Value of c-erbB-2 and p53 oncoprotein co-overexpression in human breast cancer. Anticancer Res 1997; 17:401-5; PMID:9066684
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Iwaya K, Moriya T, Yamasaki T, Tsuda H, Yamamoto J, Matsubara O. A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer. BMC Clin Pathol 2013; 13:5; PMID:23384409; https://doi.org/10.1186/1472-6890-13-5
   PubMedGoogle Scholar
• Yamamoto M, Hosoda M, Nakano K, Jia S, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y, Yamashita H. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors. Cancer Sci 2014; 105:81-8; PMID:24118529; https://doi.org/10.1111/cas.12302
   PubMed Web of Science ®Google Scholar
• Loskutova KS, Kirillina MP, Lushnikova EL, Nepomnyashchikh LM. Immunohistochemical study of apoptotic marker p53 as a prognostic factor in breast cancer. Bull Exp Biol Med 2014; 158:84-7; PMID:25403404; https://doi.org/10.1007/s10517-014-2698-3
   PubMed Web of Science ®Google Scholar
• Payandeh M, Sadeghi M, Sadeghi E, Madani SH. Expression of p53 breast cancer in Kurdish women in the West of Iran: a reverse correlation with lymph node metastasis. Asian Pac J Cancer Prev 2016; 17:1261-4; PMID:27039757; https://doi.org/10.7314/APJCP.2016.17.3.1261
   PubMedGoogle Scholar
• Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC cancer staging manual. Surgical Clin N Am 2003; 83:803-19; PMID:12875597; https://doi.org/10.1016/S0039-6109(03)00034-3
   PubMed Web of Science ®Google Scholar
• Hammond ME. ASCO-CAP guidelines for breast predictive factor testing: an update. Applied Immunohistochem Mol Morphol 2011; 19:499-500; https://doi.org/10.1097/PAI.0b013e31822a8eac
   PubMedGoogle Scholar